Advertisement

Topics

US FDA accepts regulatory submission for acalabrutinib and grants Priority Review

08:00 EDT 2 Aug 2017 | World Pharma News

AstraZenecaAstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.

Original Article: US FDA accepts regulatory submission for acalabrutinib and grants Priority Review

NEXT ARTICLE

More From BioPortfolio on "US FDA accepts regulatory submission for acalabrutinib and grants Priority Review"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...